Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
The European Commission is asking biopharma and manufacturing companies about their reaction to Novo ...
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...
The primary contractor for the project will be appointed next week. Keturah completes infrastructure work on Dubai’s first ...
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space ...
Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of ...
Gabbard has been accused of spreading Russian propaganda and former Secretary of State Hillary Rodham Clinton once referred ...
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...
At the 2024 Hindustan Times Leadership Summit, Union Minister Nitin Gadkari addressed key issues impacting India. He ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback